![Frontiers | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | Neurology Frontiers | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | Neurology](https://www.frontiersin.org/files/MyHome%20Article%20Library/696807/696807_Thumb_400.jpg)
Frontiers | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | Neurology
![Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1601469710/Copaxone.jpg/Copaxone.jpg?VersionId=PhbA.kpjNFb3A_uch5krsTbbBmdM_mNL)
Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma
![Neu gegründete Business Unit "Copaxone(R) und innovative Produkte" bei österreichischer TEVA Tochter ratiopharm | ratiopharm Arzneimittel Vertriebs GmbH, 12.10.2011 Neu gegründete Business Unit "Copaxone(R) und innovative Produkte" bei österreichischer TEVA Tochter ratiopharm | ratiopharm Arzneimittel Vertriebs GmbH, 12.10.2011](https://www.ots.at/anhang/2011/10/12/OBS/OBS_20111012_OBS0015_galerie.jpg)